Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab.

Authors :: Iannetta M
Cesta N
Stingone C
Malagnino V
Teti E
Vitale P
De Simone G
Rossi B
Ansaldo L
Compagno M
Spalliera I
Di Lorenzo A
Landi D
Nicoletti CG
Marfia GA
Andreoni M
Sarmati L
Source :: Multiple sclerosis and related disorders [Mult Scler Relat Disord] 2020 Oct; Vol. 45, pp. 102442. Date of Electronic Publication: 2020 Aug 04.
Publication Year :: 2020
Abstract: Background: Recently SARS-CoV-2 has spread worldwide causing a pandemic. Little is known about disease severity in immunocompromised hosts and people receiving disease modifying therapies (DMTs). In the last decades DMTs have been widely employed, and ocrelizumab represents one of the newest therapies for the relapsing remitting and progressive forms of multiple sclerosis (MS). Objectives: to describe SARS-CoV-2 related pneumonia in two MS patients under ocrelizumab treatment. Methods: Case series. Results: Patients showed a mild clinical course of SARS-CoV-2 related pneumonia without complications or sequelae. Conclusion: Ocrelizumab treatment is not necessarily associated to increased severity in MS patients with SARS-CoV-2 infection. Competing Interests: Declaration of Competing Interest None. (Copyright © 2020 Elsevier B.V. All rights reserved.)

Full Text Access

Tools